In the BioHarmony Drug Report Database

"Preview" Icon

Reslizumab

Cinqair, Cinqaero (reslizumab) is an antibody pharmaceutical. Reslizumab was first approved as Cinqair on 2016-03-23. It is used to treat asthma in the USA. It has been approved in Europe to treat asthma. The pharmaceutical is active against interleukin-5.

 

Trade Name

 

Cinqaero
 

Common Name

 

reslizumab
 

ChEMBL ID

 

CHEMBL2107884
 

Indication

 

asthma
 

Drug Class

 

Monoclonal antibodies: humanized, immunomodulating

Image (chem structure or protein)

Reslizumab structure rendering